MAPT and Stroke: A previous review showed that NfL, GFAP, and Tau are potential brain protein biomarkers for neurological damage; such biomarkers are released into the CSF and blood proportionally to the degree of neuron and astrocyte damage in different neurological disorders, such as stroke, traumatic brain injury, neurodegenerative dementia, and Parkinson’s disease48; however, the levels of those biomarkers used for differentiating a range of neurological diseases and monitoring disease progression need further confirmation.